Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.60 |
| ▸ | ITGAV | P06756 | 20/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 19/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961707 | 0.91 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6971933 | 0.86 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6964937 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7222480 | 0.84 | ITGB3 (0.46) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6964135 | 0.79 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6960533 | 0.77 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7222526 | 0.77 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL7222567 | 0.75 | ITGB3 (0.40) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6969100 | 0.75 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6016163 | 0.75 | ITGB3 (1.00) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586442-B2 | Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CARNIATO DENIS (FR) | 2003-07-01 | — | — | US | claimed |
| EP-1133491-B1 | NOVEL BENZOFURANE DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2003-02-19 | — | — | EP | claimed |
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2002-12-12 | — | — | US | claimed |
| US-6458801-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND ITS PRODRUG USEFUL FOR TREATING OSTEOPOROSIS. | AVENTIS PHARMA S.A. (FR) | 2002-10-01 | — | — | US | claimed |
| US-6586442-B2 | Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CARNIATO DENIS (FR) | 2003-07-01 | — | — | US | disclosed |
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2002-12-12 | — | — | US | disclosed |
| US-6458801-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND ITS PRODRUG USEFUL FOR TREATING OSTEOPOROSIS. | AVENTIS PHARMA S.A. (FR) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CYP2F1, CYP2C19, CYP2B6 | ITGB3 3038/4885ITGAV 3583/4885ITGA2B 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.